[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 395,345
  • Shares Outstanding, K 58,139
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,040 K
  • EBIT $ -135 M
  • EBITDA $ -133 M
  • 60-Month Beta 0.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.48

Options Overview Details

View History
  • Implied Volatility 120.11% (+2.57%)
  • Historical Volatility 367.02%
  • IV Percentile 54%
  • IV Rank 14.56%
  • IV High 456.20% on 12/02/25
  • IV Low 62.85% on 01/22/26
  • Expected Move (DTE 23) 1.77 (21.33%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 24,007
  • Volume Avg (30-Day) 19,320
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 160,950
  • Open Int (30-Day) 201,562
  • Expected Range 6.52 to 10.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.57
  • Number of Estimates 5
  • High Estimate $-0.40
  • Low Estimate $-0.73
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) -5.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.96 +180.07%
on 07/30/26
8.60 -3.60%
on 08/25/26
-11.41 (-57.92%)
since 07/24/26
3-Month
2.96 +180.07%
on 07/30/26
30.93 -73.20%
on 06/25/26
-20.58 (-71.29%)
since 05/22/26
52-Week
2.96 +180.07%
on 07/30/26
40.37 -79.46%
on 12/03/25
+1.69 (+25.61%)
since 08/25/25

Most Recent Stories

More News
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 62.43 (+0.16%)
CAPR : 8.29 (+21.91%)
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

CAPR : 8.29 (+21.91%)
Kaplan Fox & Kilsheimer LLP Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before September 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 62.43 (+0.16%)
CAPR : 8.29 (+21.91%)
CAPR Investor Losses: Capricor Therapeutics Clinical Data Announcement and Corresponding 64% Stock Drop Trigger Securities Class Action for Investors

Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading...

CAPR : 8.29 (+21.91%)
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , Aug. 24, 2026 /PRNewswire/ --

CAPR : 8.29 (+21.91%)
Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit Against Capricor Therapeutics, Inc. (NASDAQ: CAPR) is September 28, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

BAC : 62.43 (+0.16%)
CAPR : 8.29 (+21.91%)
Capricor Therapeutics, Inc. Investor Alert - Robbins LLP Reminds CAPR Investors with Significant Losses of the Opportunity to Lead the Class Action Lawsuit Against the Company

SAN DIEGO , Aug. 24, 2026 /PRNewswire/ -- Robbins LLP  informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired...

CAPR : 8.29 (+21.91%)
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 21, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies...

CAPR : 8.29 (+21.91%)
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - August 24, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies...

CAPR : 8.29 (+21.91%)
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman

SAN FRANCISCO , Aug. 24, 2026 /PRNewswire/ -- National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR) . Following Capricor's...

CAPR : 8.29 (+21.91%)

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 10.19
2nd Resistance Point 9.40
1st Resistance Point 8.84
Last Price 8.29
1st Support Level 7.49
2nd Support Level 6.70
3rd Support Level 6.14

See More

52-Week High 40.37
Fibonacci 61.8% 26.08
Fibonacci 50% 21.66
Fibonacci 38.2% 17.25
Last Price 8.29
52-Week Low 2.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.